Abstract: Embodiments disclosed herein provide systems and methods that increase protein yield from recombinant manufacturing processes. The systems and methods treat used depth filters with bound proteins of interest as a stationary phase exchange resin to recapture bound protein of interest from the depth filter.
Abstract: The present invention is directed to cell-based and non-cell based methods of drug screening to identify agents, or assay agents, that reduce OST-PTP or gamma-carboxylase activity or expression, or increase the level of undercarboxylated osteocalcin or adiponectin activity or expression. Such agents find use in treating or preventing a disorder related to the OST-PTP signaling pathway. Such disorders include, metabolic syndrome, glucose intolerance, type 1 or type 2 diabetes, atherosclerosis, or obesity. Such agents may be used to treat disorders characterized by decreased insulin production, deceased insulin sensitivity, and decreased glucose tolerance or increased fat mass.
Type:
Grant
Filed:
September 13, 2007
Date of Patent:
December 13, 2016
Assignee:
The Trustees of Columbia University in The City of New York
Abstract: Provided is a method of determining a therapeutic effect of cancer chemotherapy with an anticancer drug obtained by blending three ingredients, i.e., tegafur, gimeracil, and oteracil potassium as active ingredients (hereinafter abbreviated as S-1) quickly, simply, and accurately before carrying out the cancer chemotherapy. Specifically, provided is a method of determining an administration effect in chemotherapy with S-1, the method comprising: a step (a) of measuring expression level of a decorin gene in a biological sample collected from a subject to be diagnosed; and a step (b) of determining an administration effect of S-1 based on the expression level of the gene obtained from the measurement.
Type:
Grant
Filed:
March 29, 2013
Date of Patent:
November 15, 2016
Assignee:
National University Corporation Chiba University
Abstract: Disclosed is a method for suppressing the growth of a target cell, which is not limited in the type of a target cell and the type of a protein to be expressed in the target cell and needs not any preparatory experiment for determining a codon to be contained in a protein to be expressed in a target cell. Specifically disclosed is a method for suppressing the growth of a target cell, which comprises the steps of: incorporating DNA containing a region encoding a protein into the target cell, and allowing a protein encoded by the DNA to be expressed in the target cell into which the DNA has been incorporated. The region contained in the DNA comprises a tri-nucleotide sequence. The tri-nucleotide sequence is selected from codons that define at least some amino acid species constituting the protein, and is complementary to at least some codons that are used in the target cell at a frequency of 0.2 or less.
Type:
Grant
Filed:
December 2, 2009
Date of Patent:
November 15, 2016
Assignee:
JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY
Abstract: Methods and kits for lentiviral production are provided. By separating certain components of the vector including but not limited to promoter, reporter and selection marker preference components from the genetic content of interest, one can create libraries that allow for the efficient generation of custom selected lentiviral vectors.
Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
Type:
Grant
Filed:
March 9, 2010
Date of Patent:
October 11, 2016
Assignee:
Bioatla, LLC
Inventors:
Jay M. Short, Hwai Wen Chang, Gerhard Frey
Abstract: The present invention provides an approach for the determination of the activation state of discrete cell populations and/or the state of one or more cellular networks in an individual, when modulated with a modulator that acts on one cell population to communicate with other cell populations in the network. The status of discrete cell populations and/or the state of one or more cellular networks can be correlated with the diagnosis, prognosis, choice or modification of treatment, and/or monitoring of a condition, and with screening of agents.
Type:
Grant
Filed:
November 6, 2013
Date of Patent:
October 4, 2016
Assignee:
NODALITY, INC.
Inventors:
Rachael Hawtin, Drew Hotson, Alessandra Cesano, Garry P. Nolan
Abstract: The present invention relates to methods for novel drug discovery, treatment and selective targeting for Gefitinib-resistant non-small-cell lung cancer (NSCLC) harboring an additional mutation, in particular, to the discovery of a drug candidate or agent identified by the presently claimed method for use in treating and selective targeting Gefitinib-resistant NSCLC harboring T790M mutation.
Type:
Grant
Filed:
June 5, 2014
Date of Patent:
September 13, 2016
Assignee:
Macau University of Science and Technology
Inventors:
Elaine Lai-Han Leung, Liang Liu, Xing-Xing Fan
Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
Type:
Grant
Filed:
April 3, 2015
Date of Patent:
August 23, 2016
Assignee:
ONCOMED PHARMACEUTICALS, INC.
Inventors:
Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
Abstract: A cosmetic use of at least one C-glycoside derivative in a composition comprising a physiologically acceptable medium, as a cosmetic agent for promoting the desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal.
Type:
Grant
Filed:
June 29, 2007
Date of Patent:
August 23, 2016
Assignee:
L'OREAL
Inventors:
Maria Dalko, Christophe Boulle, Dominique Bernard
Abstract: Disclosed are a medium for mammalian somatic cells with which mammalian somatic cells can be grown effectively when the mammalian somatic cells are cultured, while reducing the amount of serum to be added to the medium as much as possible or without adding serum thereto, and an additive to constitute the medium. By blending of a ligand for an endothelial cell differentiation gene (Edg) family receptor and a ligand for a serotonin receptor to a medium, somatic cells of mammals can be grown even in cases where the medium does not contain serum at all or contains only a small amount thereof.
Abstract: A method for producing from host cells a heterologous polypeptide or protein comprising at least one cysteine residue in a reduced state. The method cultured the host cells in a culture medium comprising a reducing agent; and recovered the heterologous polypeptide or protein comprising at least one cysteine residue in a reduced state from the host cells or from the culture medium, where the host cells comprise a nucleic acid encoding the heterologous protein or polypeptide, and where the reducing agent is capable of permeating the plasma membrane of the host cells.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
August 9, 2016
Assignee:
Thermo Fisher Scientific Baltics UAB
Inventors:
Juozas {hacek over (S)}iurkus, Peter Neubauer
Abstract: The present invention provides methods and compositions for diagnosing and predicting the occurrence of ischemia. For example, the present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient neurological events (TNE) as ischemic or non-ischemic.
Type:
Grant
Filed:
January 4, 2013
Date of Patent:
August 9, 2016
Assignee:
The Regents of the University of California
Abstract: This invention includes a process for the identification and validation of a neutral polynucleotide integration site within the S. spinosa genome. In addition, the invention includes the use of the neutral site and methods for the integration of a polynucleotide containing a gene expression cassette, which is stably maintained and expressed over subsequent generations. The invention includes neutral integration sites that can be disrupted without negatively impacting spinosyn production, growth or other desired metabolic characteristics.
Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.
Abstract: The genomic DNA of Streptoverticillium sp. 3-7, which produces UK-2, was analyzed to identify a region expected to be a UK-2 biosynthetic gene cluster. Moreover, by colony hybridization, DNAs in the region were successfully isolated. Further, the DNAs were used to prepare a strain in which the genes present in the region were disrupted. The strain was found not to produce UK-2. It was verified that the genomic region was the UK-2 biosynthetic gene cluster. Furthermore, Streptoverticillium sp. 3-7 was transformed by introduction of a vector in which the isolated UK-2 biosynthetic gene cluster was inserted. It was also found out that the UK-2 productivity by the transformant was improved about 10 to 60 times or more in comparison with that of the parental strain. Moreover, it was revealed that 2 copies of the UK-2 biosynthetic gene cluster were present per cell in these transformants, respectively.
Type:
Grant
Filed:
July 8, 2013
Date of Patent:
June 14, 2016
Assignee:
MEIJI SEIKA PHARMA CO., LTD.
Inventors:
Koei Kobayashi, Naomi Sumida, Koji Yanai
Abstract: Systems and methods for analyzing copy number of a target locus, detecting a disease associated with abnormal copy number of a target gene or a carrier thereof.
Type:
Grant
Filed:
November 12, 2010
Date of Patent:
June 7, 2016
Assignee:
ESOTERIX GENETIC LABORATORIES, LLC
Inventors:
Viatcheslav R. Akmaev, Brant Hendrickson, Thomas Scholl
Abstract: A method for producing a recombinant protein includes steps of: (a) culturing a transformed cell in a protein-free and lipid-free medium containing no exogenous growth factors, in which the transformed cell is produced by transfecting a cell of a cell line derived from Chinese Hamster Ovary (CHO) cells, the cell line is adapted to a protein-free and lipid-free medium, and the cell is capable of proliferating in a suspended state in a protein-free and lipid-free medium containing no exogenous growth factors, with a vector containing a gene coding for the protein to be produced under the control of a promoter operable in the cell, and (b) recovering the protein produced by the transformed cell.
Type:
Grant
Filed:
February 21, 2014
Date of Patent:
May 17, 2016
Assignees:
Kyokuto Pharmaceutical Industrial Co., Ltd., National Institute for Materials Science
Abstract: This disclosure provides methods and compositions for tagging long fragments of a target nucleic acid for sequencing and analyzing the resulting sequence information in order to reduce errors and perform haplotype phasing, for example.
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
May 3, 2016
Assignee:
COMPLETE GENOMICS, INC.
Inventors:
Radoje Drmanac, Brock A. Peters, Andrei Alexeev